Pre-print here: https://www.medrxiv.org/content/10.1101/2021.10.12.21264773v1
Most interesting part:
The primary outcome (n=209), rates of post-intervention progression to CDP, were assessed over three years. Between June 24, 2014 and September 11, 2018, 1,200 patients were enrolled, 963 randomized (BIS n=482;TM n=481) and 879 analyzed (BIS n=442;TM n=437). Median follow-up was 32.9 months (IQR=22,35). BIS patients triggered an intervention at a lower rate than TM patients (20.1%, n=89 vs 27.5%, n=120, p = 0.011). Median months to trigger was longer with BIS than TM (9.7; 95%CI,8.2-12.6 vs 3.9; 95%CI,2.8-4.5, p = 0.001). Overall, 14.4%(n=30) progressed post-intervention, with reduced likelihood for BIS patients than TM patients (7.9%, n=7 vs 19.2%, n=23; RR=0.41; 95%CI,0.13-0.81; absolute reduction 11.3%; 95%CI,2.3%-20.3%; p = 0.016). Conclusions: As compared to TM, BIS provides a more precise identification of patients likely to benefit from an early compression intervention.
- Forums
- ASX - By Stock
- IPD
- PREVENT paper avail
PREVENT paper avail
Featured News
Add IPD (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.8¢ |
Change
0.004(4.76%) |
Mkt cap ! $178.0M |
Open | High | Low | Value | Volume |
8.5¢ | 9.3¢ | 8.5¢ | $176.6K | 2.009M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 11935 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.087 |
1 | 1603 | 0.086 |
1 | 1603 | 0.085 |
1 | 601 | 0.084 |
2 | 11787 | 0.083 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 11935 | 1 |
0.092 | 461789 | 3 |
0.093 | 324100 | 3 |
0.094 | 7809 | 1 |
0.095 | 713529 | 5 |
Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
Last
8.8¢ |
  |
Change
0.004 ( 5.52 %) |
|||
Open | High | Low | Volume | ||
8.5¢ | 9.2¢ | 8.5¢ | 393667 | ||
Last updated 15.07pm 16/05/2024 ? |
Featured News
IPD (ASX) Chart |